Lung Cancer

Data from an updated analysis of the phase 3 PACIFIC trial indicate that treatment with durvalumab after chemoradiotherapy is associated with long-term survival improvements in patients with unresectable stage III non-small cell lung cancer.

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.

Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Christian Grohé, MD, and Gary Doherty, MRCP, PhD, consider factors that may influence the resectability of patients with stage IIIA-N2 disease, such as biomarker status, performance status, and imaging results.

A panel of experts in the management of lung cancer share key insights into challenges associated with retesting for driver mutations, tumor heterogeneity, and potential differences between biopsy and surgical sample test results.

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

The European Commission has approved osimertinib for the adjuvant treatment of adult patients with early-stage EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.

Pembrolizumab alone and in combination with chemotherapy was associated with shorter overall survival compared with the data demonstrated in the registrational clinical trials in older Medicare patients with advanced non–small cell lung cancer, providing real-world insight into the prognosis of older patients with NSCLC who are treated with immunotherapy.

Gary Doherty, MRCP, PhD, and Christian Grohé, MD, discuss the multidisciplinary approach to molecular testing for EGFR mutations in NSCLC and the importance of reflex testing to limit delays in receiving results.

Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.

Solange Peters, MD, PhD, reviews factors to consider for molecular testing in early stage non–small cell lung cancer and discusses the role of single-gene assays and next-generation sequencing panels.

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

Andrea Saltos, MD, provides perspective on the use of targeted therapy across EGFR-, RET-, and MET-positive NSCLC.

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab for use in 2 advanced cancers: non–small cell lung cancer and basal cell carcinoma.